Needham analyst David Saxon reiterated a Buy rating on Alcon yesterday and set a price target of $98.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Saxon has given his Buy rating due to a combination of factors that underscore Alcon’s solid fundamental trajectory and market recovery signals. Fourth-quarter 2025 revenue growth of about 7% in constant currency essentially matched expectations, and 2026 guidance for both sales and earnings points to outcomes that are broadly in line with, or slightly ahead of, current Street forecasts.
In addition, Saxon highlights that equipment sales expanded roughly 18% in constant currency, driving a notable improvement in the Surgical segment, while early uptake of Tryptyr, alongside Systane, indicates healthy momentum in Vision Care. Coupled with indications from peers such as Bausch + Lomb and Johnson & Johnson that the broader eye-care market modestly improved in late 2025, these dynamics support a constructive outlook that, in his view, justifies a Buy recommendation on ALC shares.
According to TipRanks, Saxon is an analyst with an average return of -0.3% and a 36.69% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Azenta, Cooper Co, and Glaukos.
In another report released on February 18, BTIG also maintained a Buy rating on the stock with a $91.00 price target.